We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Poor diagnosis

26 April 2016 By Robyn Mak

Regulators say the e-commerce group’s 2014 investment into its health unit breached takeover rules. Details are scarce and Alibaba does not have to compensate shareholders. Even so, the latest run-in is another reason for Hong Kong investors to be wary of Jack Ma’s company.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)